Latest Articles

Publication Date
Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data - Nature

Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data Nature

Published: Sept. 1, 2025, 5:12 a.m.
Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data.

Triptorelin, a gonadotropin-releasing hormone(GnRH) agonist, is approved by the US Food and Drug Administration(FDA) for treating advanced prostate cancer, endometriosis, and central precocious puberty(CPP) in children aged ≥ 2 years. …

Published: Sept. 1, 2025, midnight
The Role of GnRH Agonist Therapy and Hysterosalpingography (HSG) in Diagnosing and Treating Tubal Factor Infertility.

The paper describes the treatment of a 27-year-old woman with a history of infertility, heavy menstrual periods, and severe endometriosis with bilateral hydrosalpinx. The patient received hormonal treatment with triptorelin …

Published: Dec. 5, 2024, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!